Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

Tsao, Ming Sound; Carbone, Michele; Galateau-Salle, Françoise; Moreira, André L.; Nicholson, Andrew G.; Roden, Anja C.; Adjei, Alex A.; Aubry, Marie Christine; Fennell, Dean A.; Gomez, Daniel R.; Harpole, David H.; Hesdorffer, Mary; Hirsch, Fred R.; Liu, Geoffrey; Malik, Shakun; Nowak, Anna K.; Peikert, Tobias; Salgia, Ravi; Szlosarek, Peter W.; Taioli, Emanuela; Yang, Haining; Tsao, Anne S.; Mansfield, Aaron S.

doi:10.1016/j.jtho.2019.06.020

Cited by 10 publications

(3 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytologically recognized MMs often show papillary differentiation. This phenotype is, however, considered more indolent, 26-28 and could not explain the improved survival. In a recent study, integrated molecular pathology could demonstrate that six clusters of genetic aberration in MM showed distinct survival outcomes 29 .…”

Section: Discussionmentioning

confidence: 90%

Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis

Own

Höijer

Hillerdahl

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

A conclusive diagnosis of malignant mesothelioma (MM) can be based on effusion cytology using the guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type MM. Briefly, the diagnosis is obtained when the mesothelial phenotype of malignant cells is established by ancillary techniques. This study is based on the comparison of the overall survival rates of patients with MM when diagnosed by effusion cytology, histopathology, or a combination of both. A total of 144 patients were diagnosed with epithelioid and mixed‐type pleural MM at Karolinska University Hospital between 2004 and 2013. The diagnosis was obtained by histopathology in 74 cases and by cytological examination of pleural effusion in 70 cases. In 29 of the latter cases, a diagnostic biopsy was obtained simultaneously. A total of 104 patients received chemotherapy. All diagnoses were supported by clinical findings, including computer tomography scans. The median time between first symptoms and diagnosis was similar for cytology and histopathology. However, a delay of more than 6 months after first symptoms was seen in many patients in the histopathology group, resulting in late onset of treatment. The overall survival and proportion of long‐term survival were significantly better for cases diagnosed by cytology. Similarly, a better survival, following a cytological diagnosis, was also seen in patients who were only provided the best supportive care. Accurate cytological diagnosis enables conclusive diagnosis of MM. Our finding enables the initiation of treatment as soon as the cytological diagnosis is established, avoiding further delay and deterioration of patient survival and possibilities for treatment.

show abstract

Section: Discussionmentioning

confidence: 90%

Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis

Own

Höijer

Hillerdahl

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…However, the evaluation of the pathological assessment is performed on tumor material, usually taken by invasive procedures at diagnosis as thoracoscopic biopsies or computed tomography-guided biopsy. These techniques, although tested and efficient, are associated with considerable morbidity and cost, and cannot always be performed due to specific patient conditions (37,38).…”

Section: Discussionmentioning

confidence: 99%

Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma

et al. 2020

View full text Add to dashboard Cite

“…There is a critical need for a sensitive and specific noninvasive screening method of high risk, asbestosexposed populations to potentially diagnose and treat mesothelioma at earlier stages. In the absence of strong and reliable noninvasive diagnostic tests, currently, pleural biopsy remains the only standard diagnostic method for MPM, associated with considerable morbidity and costs (34). The complication rate and morbidity associated with pleural biopsy depends on various patient and procedure-related factors.…”

Section: Introductionmentioning

confidence: 99%

Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network

Pass

Alimi

Carbone

et al. 2020

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an asbestos-related neoplasm, which can be treated successfully only if correctly diagnosed and treated in early stages. The asbestos-exposed population serves as a high-risk group that could benefit from sensitive and specific blood-or tissue-based biomarkers. This review details the recent work with biomarker development in MPM and the contributions of the NCI Early Detection Research Network Biomarker Developmental Laboratory of NYU Langone Medical Center. The literature of the last 20 years was reviewed to comment on the most promising of the blood-and tissue-based biomarkers. Proteomic, genomic, and epigenomic platforms as well as novel studies such as "breath testing" are covered. Soluble mesothelin-related proteins (SMRP) have been characterized extensively and constitute an FDA-approved biomarker in plas-ma with diagnostic, monitoring, and prognostic value in MPM. Osteopontin is found to be a valuable prognostic biomarker for MPM, while its utility in diagnosis is slightly lower. Other biomarkers, such as calretinin, fibulin 3, and High-Mobility Group Box 1 (HMGB1), remain under study and need international validation trials with large cohorts of cases and controls to demonstrate any utility. The EDRN has played a key role in the development and testing of MPM biomarkers by enlisting collaborations all over the world. A comprehensive understanding of previously investigated biomarkers and their utility in screening and early diagnosis of MPM will provide guidance for further future research.See all articles in this CEBP Focus section, "NCI Early Detection Research Network: Making Cancer Detection Possible."

show abstract

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

Abstract: and has a patent pending regarding BAP1, and patents issued regarding using anti-HMGB1 monoclonal antibody or other HMGB1 antibodies as a novel mesothelioma therapeutic strategy, and HMGB1 as a biomarker for asbestos exposure and mesothelioma early detection. Dr.

Cited by 10 publications

References 128 publications

Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis

Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis

Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma

Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network

Contact Info

Product

Resources

About